<DOC>
	<DOC>NCT01093664</DOC>
	<brief_summary>This is a phase IB follow-up study to assess a boost immunization with AFFITOPE AD02 with regard to safety/tolerability, immunological and clinical activity in Alzheimer patients who have received the vaccine within the clinical study AFF002.</brief_summary>
	<brief_title>Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Participation in AFF002 and AFF004 Presence or history of allergy to components of the vaccine, if considered relevant by the investigator Contraindication for MRI imaging History and/or presence of autoimmune disease, if considered relevant by the investigator Active infectious disease (e.g., Hepatitis B, C) Presence and/or history of Immunodeficiency (e.g., HIV) Significant systemic illness</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>